Defects in Ca2+ release associated with local expression of pathological ryanodine receptors in mouse muscle fibres

Journal of Physiology

Volumn 589, Issue 22, 2011, Pages 5361-5382

  Lefebvre, Romain ^a   Legrand, Claude ^a   González Rodríguez, Estela ^b   Groom, Linda ^c   Dirksen, Robert T ^c   Jacquemond, Vincent ^a  

^a CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY OF ALICANTE   (Spain)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; RYANODINE RECEPTOR; CALCIUM; ENHANCED GREEN FLUORESCENT PROTEIN; FLUORESCENT DYE; FUSED HETEROCYCLIC RINGS; GREEN FLUORESCENT PROTEIN; RHOD 2; RHOD-2;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CELL DIFFERENTIATION; CHANNEL GATING; CONTROLLED STUDY; DEPOLARIZATION; ENZYME ACTIVATION; ENZYME REGULATION; ENZYME RELEASE; HOMEOSTASIS; MALE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOPLASMIC RETICULUM; VOLTAGE CLAMP; ANIMAL; CONFOCAL MICROSCOPY; METABOLISM; MUSCLE DISEASE; MUTATION; PATCH CLAMP; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; CALCIUM; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; HETEROCYCLIC COMPOUNDS, 3-RING; MALE; MICE; MICROSCOPY, CONFOCAL; MUSCLE FIBERS, SKELETAL; MUSCULAR DISEASES; MUTATION; PATCH-CLAMP TECHNIQUES; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 81255177588     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2011.216408     Document Type: Article

References (49)

1. 2+ release in muscle fibers of Y522S RyR1 knock-in mice. Proc Natl Acad Sci U S A 106, 4531-4536.
2. Avila G & Dirksen RT (2001). Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J Gen Physiol 118, 277-290.
3. 2+ channel expression. J Biol Chem 276, 17732-17738.
4. Avila G, O'Connell KM & Dirksen RT (2003). The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease. J Gen Physiol 121, 277-286.
5. Boncompagni S, Loy RE, Dirksen RT & Franzini-Armstrong C (2010). The I4895T mutation in the type 1 ryanodine receptor induces fiber-type specific alterations in skeletal muscle that mimic premature aging. Aging Cell 9, 958-970.
6. Chelu MG, Goonasekera SA, Durham WJ, Tang W, Lueck JD, Riehl J, Pessah IN, Zhang P, Bhattacharjee MB, Dirksen RT & Hamilton SL (2006). Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. FASEB J 20, 329-330.
7. Cheng H, Lederer WJ & Cannell MB (1993). Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. Science 262, 740-744.
8. Collet C, Pouvreau S, Csernoch L, Allard B & Jacquemond V (2004). Calcium signaling in isolated skeletal muscle fibers investigated under "Silicone Voltage-Clamp" conditions. Cell Biochem Biophys 40, 225-236.
9. 2+ concentration in mouse skeletal muscle fibers with the fluorescent indicator mag-indo-1. Biophys J 75, 957-967.
10. Davis MR, Haan E, Jungbluth H, Sewry C, North K, Muntoni F, Kuntzer T, Lamont P, Bankier A, Tomlinson P, Sánchez A, Walsh P, Nagarajan L, Oley C, Colley A, Gedeon A, Quinlivan R, Dixon J, James D, Müller CR & Laing NG (2003). Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromuscul Disord 13, 151-157.
11. Di Franco M, Quinonez M, Capote J & Vergara J (2009). DNA transfection of mammalian skeletal muscles using in vivo electroporation. J Vis Exp 32, 1520.
12. 2+ release. J Physiol 526, 507-514.
13. 2+ release channels? Trends Cardiovasc Med 12, 189-197.
14. 2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 87, 3193-3204.
15. Drummond GB (2009). Reporting ethical matters in The Journal of Physiology: standards and advice. J Physiol 587, 713-719.
16. Ducreux S, Zorzato F, Müller C, Sewry C, Muntoni F, Quinlivan R, Restagno G, Girard T & Treves S (2004). Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. J Biol Chem 279, 43838-43846.
17. Dulhunty AF (2006). Excitation-contraction coupling from the 1950s into the new millennium. Clin Exp Pharmacol Physiol 33, 763-772.
18. Durham WJ, Aracena-Parks P, Long C, Rossi AE, Goonasekera SA, Boncompagni S, Galvan DL, Gilman CP, Baker MR, Shirokova N, Protasi F, Dirksen R & Hamilton SL (2008). RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 133, 53-65.
19. Ferrington DA, Krainev AG & Bigelow DJ (1998). Altered turnover of calcium regulatory proteins of the sarcoplasmic reticulum in aged skeletal muscle. J Biol Chem 273, 5885-5891.
20. Hernandez-Lain A, Husson I, Monnier N, Farnoux C, Brochier G, Lacène E, Beuvin M, Mait Viou, Manéré L, Claeys KG, Fardeau M, Lunardi J, Voit T & Romero NB (2011). De novo RYR1 heterozygous mutation (I4898T) causing lethal core-rod myopathy in twins. Eur J Med Genet 54, 29-33.
21. Hogan K, Couch F, Powers PA & Gregg RG (1992). A cysteine-for-arginine substitution (R614C) in the human skeletal muscle calcium release channel cosegregates with malignant hyperthermia. Anesth Analg 75, 441-448.
22. Jacquemond V (1997). Indo-1 fluorescence signals elicited by membrane depolarization in enzymatically isolated mouse skeletal muscle fibers. Biophys J 73, 920-928.
23. 2+ release in adult mouse skeletal muscle fibres expressing the type 3 ryanodine receptor. J Physiol 586, 441-457.
24. 2+ ion permeation and release from the sarcoplasmic reticulum. J Gen Physiol 137, 43-57.
25. Lyfenko AD, Ducreux S, Wang Y, Xu L, Zorzato F, Ferreiro A, Meissner G, Treves S & Dirksen RT (2007). Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle excitation-contraction (EC) coupling by distinct mechanisms. Hum Mutat 28, 61-68.
26. 2+ in malignant hyperthermia and central core disease. Biochem Biophys Res Commun 322, 1256-1266.
27. 2+ release channel function and severe central core disease. Proc Natl Acad Sci U S A 30, 4164-4169.
28. McCarthy TV, Quane KA & Lynch PJ (2000). Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 15, 410-417.
29. McLennan DH & Zvaritch E (2011). Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum. Biochim Biophys Acta 1813, 948-964.
30. Manning BM, Quane KA, Ording H, Urwyler A, Tegazzin V, Lehane M, O'Halloran J, Hartung E, Giblin LM, Lynch PJ, Vaughan P, Censier K, Bendixen D, Comi G, Heytens L, Monsieurs K, Fagerlund T, Wolz W, Heffron JJ, Muller CR & McCarthy TV (1998). Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 62, 599-609.
31. Melzer W & Dietze B (2001). Malignant hyperthermia and excitation-contraction coupling. Acta Physiol Scand 171, 367-378.
32. Pape PC, Jong DS & Chandler WK (1995). Calcium release and its voltage dependence in frog cut muscle fibers equilibrated with 20 mM EGTA. J Gen Physiol 106, 259-336.
33. 2+ release in the presence of maurocalcine in skeletal muscle. Biophys J 91, 2206-2215.
34. Quane KA, Keating KE, Healy JM, Manning BM, Krivosic-Horber R, Krivosic I, Monnier N, Lunardi J & McCarthy TV (1994). Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 23, 236-239.
35. Rios E & Pizarro G (1991). Voltage sensor of excitation-contraction coupling in skeletal muscle. Physiol Rev 71, 849-908.
36. Robinson R, Carpenter D, Shaw MA, Halsall J & Hopkins P (2006). Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27, 977-989.
37. Royer L, Sztretye M, Manno C, Pouvreau S, Zhou J, Knollmann BC, Protasi F, Allen PD & Ríos E (2010). Paradoxical buffering of calcium by calsequestrin demonstrated for the calcium store of skeletal muscle. J Gen Physiol 136, 325-338.
38. Struk A, Lehmann-Horn F & Melzer W (1998).Voltage-dependent calcium release in human malignant hyperthermia muscle fibers. Biophys J 75, 2402-2410.
39. Treves S, Anderson AA, Ducreux S, Divet A, Bleunven C, Grasso C, Paesante S & Zorzato F (2005). Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscul Disord 15, 577-587.
40. Treves S, Jungbluth H, Muntoni F & Zorzato F (2008). Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 8, 319-326.
41. Trollet C, Bloquel C, Scherman D & Bigey P (2006). Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther 6, 561-578.
42. Wilmshurst JM, Lillis S, Zhou H, Pillay K, Henderson H, Kress W, Müller CR, Ndondo A, Cloke V, Cullup T, Bertini E, Boennemann C, Straub V, Quinlivan R, Dowling JJ, Al-Sarraj S, Treves S, Abbs S, Manzur AY, Sewry CA, Muntoni F & Jungbluth H (2010). RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann Neurol 68, 717-726.
43. Yang T, Allen PD, Pessah IN & Lopez JR (2007a). Enhanced excitation-coupled calcium entry in myotubes is associated with expression of RyR1 malignant hyperthermia mutations. J Biol Chem 282, 37471-37478.
44. i in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR. Am J Physiol Cell Physiol 292, C1591-C1598.
45. Yang T, Riehl J, Esteve E, Matthaei KI, Goth S, Allen PD, Pessah IN & Lopez JR (2006). Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse. Anesthesiology 105, 1164-1175.
46. Yang T, Ta TA, Pessah IN & Allen PD (2003). Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 278, 25722-25730.
47. Zhou H, Lillis S, Loy RE, Ghassemi F, Rose MR, Norwood F, Mills K, Al-Sarraj S, Lane RJ, Feng L, Matthews E, Sewry CA, Abbs S, Buk S, Hanna M, Treves S, Dirksen RT, Meissner G, Muntoni F & Jungbluth H (2010). Multi-minicore disease and atypical periodic paralysis associated with novel mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 20, 166-173.
48. 2+ release channel function and delays development in homozygous offspring of a mutant mouse line. Proc Natl Acad Sci U S A 104, 18537-18542.
49. 2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods. Proc Natl Acad Sci U S A 106, 21813-21818.